Do digestive enzyme pills work? The evidence splits sharply by who takes them

"Digestive enzymes" describes two very different products sold under one name. One is a prescription medicine with decades of randomised evidence. The other is an over-the-counter capsule marketed to otherwise healthy people for bloating, and its evidence base is thin. Confusing the two is how the supplement aisle borrows credibility it has not earned.

Where enzymes clearly work

When the pancreas cannot produce enough of its own digestive enzymes — a state called exocrine pancreatic insufficiency, caused by cystic fibrosis, chronic pancreatitis, pancreatic cancer or surgery — food passes through undigested, and fat in particular is lost in the stool. Pancreatic enzyme replacement therapy, or PERT, supplies those enzymes in acid-protected capsules taken with meals.

A 2026 systematic review and meta-analysis pooled 14 randomised trials of 684 patients comparing PERT with placebo [s1]. The effect on fat absorption was large: a standardised mean difference of 1.57 (95% confidence interval 1.20 to 1.94) [s1]. Protein absorption improved too, with a standardised mean difference of 1.52 (95% CI 0.97 to 2.06) [s1]. The benefit held across causes — cystic fibrosis and chronic pancreatitis alike showed significant gains in fat absorption [s1]. A separate Cochrane review of PERT in cystic fibrosis reached the same practical conclusion: the therapy is standard care because withholding it causes measurable harm [s2].

This is what strong evidence for an enzyme supplement looks like — placebo-controlled trials, objective absorption measurements, and a clear biological reason the pills are needed. The people who benefit are those whose bodies genuinely cannot make the enzyme.

Where the evidence gets shaky

Most digestive-enzyme capsules are not bought by people with pancreatic disease. They are bought by people with bloating, gas and irregular bowels who have been told a broad enzyme "complex" will help them break down food. Here the evidence thins out fast.

The most-cited recent study of such a product is a 2026 report on a FODMAP-targeting enzyme blend — enzymes meant to break down the fermentable carbohydrates that trigger symptoms in irritable bowel syndrome [s3]. Its headline numbers sound impressive: after four weeks, 78.0% of users reported improved bloating and flatulence (95% CI 69.7% to 84.5%), and 65.3% reported less abdominal pain (95% CI 56.3% to 73.2%) [s3].

Read the methods, though, and the numbers deflate. It was a single-arm, open-label, pre-post cohort study of people who had already bought the enzymes online and filled in anonymous surveys before and after [s3]. There was no placebo group, no randomisation, no blinding, and no comparison with doing nothing [s3]. In gut-brain disorders such as IBS, placebo response rates routinely run above a third — as they did in rigorous peppermint-oil trials — so a design with no control cannot tell you how much of that 78% is the enzyme and how much is expectation, regression to the mean, and the natural waxing and waning of symptoms. The authors say as much, calling it "a promising first report" that needs further research [s3].

The honest summary

Enzyme supplements are strongly supported for one job: replacing enzymes the body cannot make. If you have cystic fibrosis, chronic pancreatitis or another cause of pancreatic insufficiency, PERT is evidence-based treatment, not a wellness product [s1][s2]. Lactase tablets for diagnosed lactose intolerance sit in a similar category — a specific missing enzyme, replaced.

For a general "digestive enzyme complex" taken for everyday bloating, the honest position is that the best available study cannot separate the product from placebo [s3]. That is not proof it does nothing; it is an absence of the kind of evidence that would show it does something. The distinction matters because these capsules are not free, and bloating that is worth medicating is also worth diagnosing — the same symptoms can signal coeliac disease, IBS or, rarely, the pancreatic insufficiency for which enzymes are actually indicated.

What would change the picture

The evidence gap here is fixable. A randomised, placebo-controlled trial of an over-the-counter enzyme blend, using a validated symptom score and a blinded comparison against an identical dummy capsule, would settle whether the effect survives a control group. Until one exists, the split stands: proven where the enzyme is genuinely missing and measured against placebo, unproven where the capsule is sold as a general digestive aid to people whose own enzymes work fine.

Sources

• Efficacy of pancreatic enzyme replacement therapy on exocrine pancreatic insufficiency: a systematic review and meta-analysis — European Journal of Gastroenterology & Hepatology, 2026-06-12
• Pancreatic enzyme replacement therapy for people with cystic fibrosis — Cochrane Database of Systematic Reviews, 2020-08-06
• FODMAP-Targeting Digestive Enzyme Blend for Management of Gastrointestinal Symptoms: A Real-World Pre-Post Intervention Cohort Study — Gastro Hep Advances, 2026-02-14